Apollo Therapeutics (‘Apollo 1; Apollo Therapeutics LLP), a collaboration between three leading universities (University College London, Imperial College and University of Cambridge) and three global pharmaceutical companies (AstraZeneca, GlaxoSmithKline and Johnson & Johnson) was set up in late 2015 as a fund of £40M (£30M from the pharma partners and £10M from the universities). A second fund raise generated £103M/$145M in investment to further develop and translate early-stage science into clinical development for patient benefit. In order to translate research in the most time and capital efficient way possible, as at 16/06/2021, the ‘Apollo 2’ fund, Apollo Therapeutics Group Ltd, has been set up as a portfolio-based biopharmaceutical company with a £103M Series A financing deal. The financing was led by Patient Square Capital, with participation from additional investors including UCL Technology Fund, Rock Springs Capital and Reimagined Ventures.